ReviewInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2020
Discovery and development of safe-in-man broad-spectrum antiviral agents.
Review in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 122 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
122 citing papers in PubMed, 2 syntheses or guidelines pooled it, 271 citations in OpenAlex.
- The life cycle of the alphaviruses: From an antiviral perspective.Antiviral research · 2023Pooled it
- Computational drug discovery and repurposing for the treatment of COVID-19: A systematic review.Bioorganic chemistry · 2021Pooled it
- Towards broader-spectrum direct-acting antivirals against RNA viruses.Nature reviews. Microbiology · 2026Review
- A multi-view feature fusion framework with interpretable graph convolution for predicting microbe-drug associations.BMC bioinformatics · 2026Article
- Standardizing antiviral response metrics for mono- and combination therapies in acute, chronic and latent viral infections.Virology journal · 2026Review
- A microbe-drug association prediction model based on graph attention networks and rotation forest.Frontiers in bioinformatics · 2026Article
- Combination of vemurafenib, pleconaril, and AG7404 attenuates enterovirus replicationNAR molecular medicine · 2026Article
- HAFMMDA: HIN2vec-Based Attentional Factorization Machines for Predicting Microbe-Drug Associations.Interdisciplinary sciences, computational life sciences · 2025Article
- KGCLMDA: a computational model for predicting latent associations of microbial drugs using knowledge graphs and contrastive learning.Bioinformatics (Oxford, England) · 2025Article
- AEPMA: peptide-microbe association prediction based on autoevolutionary heterogeneous graph learning.Briefings in bioinformatics · 2025Article
- Selected strains of the Ganoderma lucidum complex from Finnish forests have excellent broadly acting antiviral properties.Scientific reports · 2025Article
- NRGCNMDA: Microbe-Drug Association Prediction Based on Residual Graph Convolutional Networks and Conditional Random Fields.Interdisciplinary sciences, computational life sciences · 2025Article
- JAK inhibitors remove innate immune barriers facilitating viral propagation.NAR molecular medicine · 2025Article
- Host centric drug repurposing for viral diseases.PLoS computational biology · 2025Article
- GiGs: graph-based integrated Gaussian kernel similarity for virus-drug association prediction.Briefings in bioinformatics · 2025Article
- Article
- DHCLHAM: microbe-drug interaction prediction based on dual-hypergraph contrastive learning framework with hierarchical attention mechanism.Frontiers in microbiology · 2025Article
- CLMT: graph contrastive learning model for microbe-drug associations prediction with transformer.Frontiers in genetics · 2025Article
- Article
- Review
62 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Viral diseases are one of the leading causes of morbidity and mortality in the world. Virus-specific vaccines and antiviral drugs are the most powerful tools to combat viral diseases. However, broad-spectrum antiviral agents (BSAAs, i.e. compounds targeting viruses belonging to two or more viral families) could provide additional protection of the general population from emerging and re-emerging viral diseases, reinforcing the arsenal of available antiviral options. Here, we review discovery and development of BSAAs and summarize the information on 120 safe-in-man agents in a freely accessible database (https://drugvirus.info/). Future and ongoing pre-clinical and clinical studies will increase the number of BSAAs, expand the spectrum of their indications, and identify drug combinations for treatment of emerging and re-emerging viral infections as well as co-infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.